Eritoran increases survival in animal models of bacterial sepsis (18), but it did not improve clinical outcomes in a phase III clinical trial in patients with septic shock (42). https://t.co/UnGhBYuF1f
138 followers
1,900 followers
We have an (ego?) problem when we think we can "tune" or "improve" a mechanism that had millions of years to tune & refine via evolution: Recognising PAMPs (common pathogen patterns) & activating the same pathways (NF-kb, TNF) over and over again
1,367 followers
Along the same lines, we fail to improve mortality when we block pathways responsible for #fever and other findings of #sepsis syndrome https://t.co/9aDishj69I
90 followers
e-nfectologiaped: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis:... http://t.co/N68w5vwugu